Cubist Systematic Strategies, LLC Bristol Myers Squibb CO Put Options Transaction History

Cubist Systematic Strategies, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $13.2 Million - $17.2 Million	331,800 Added 301.36%	441,900 $22.9 Million
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $1.83 Million - $2.41 Million	45,400 Added 70.17%	110,100 $4.57 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $1.5 Million - $1.7 Million	-31,200 Reduced 32.53%	64,700 $3.51 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $300,576 - $358,670	6,200 Added 6.91%	95,900 $4.92 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $943,607 - $1.06 Million	16,300 Added 22.21%	89,700 $5.21 Million
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $2.22 Million - $2.47 Million	-34,900 Reduced 32.23%	73,400 $4.69 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $1.7 Million - $1.93 Million	-25,900 Reduced 19.3%	108,300 $7.51 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $1.03 Million - $1.22 Million	15,100 Added 12.68%	134,200 $9.65 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $1,469 - $868,292	-11,300 Reduced 8.67%	119,100 $8.47 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $9.47 Million - $10.4 Million	130,400 New	130,400 $10 Million

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.